Daniel Chevallard
Director of Finance/CFO at Viracta Subsidiary, Inc.
Net worth: 135 908 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph Hagan | M | 55 | 8 years | |
| Roger Pomerantz | M | 67 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
| Ivor Royston | M | 79 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Barry Simon | M | 59 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 7 years |
| Michael Huang | M | 50 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
| Mark Rothera | M | 61 | 2 years | |
| Melody Burcar | F | 41 | 2 years | |
| Gur Roshwalb | M | 55 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
| William Rastetter | M | 76 | 11 years | |
| Flavia Borellini | M | 64 | 3 years | |
| Jane Chung | F | 53 | 2 years | |
| Daniel Penksa | M | 39 | 9 years | |
| Stephen Rubino | M | 65 | 3 years | |
| Jim Woody | M | 81 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Jane Barlow | M | 63 | 3 years | |
| Kathryn J. Collier | F | 56 | 6 years | |
| Thomas Darcy | M | 74 | 3 years | |
| Pascale Witz | F | 57 | 7 years | |
| Jake Nunn | M | 53 | 5 years | |
| Hugh Rosen | M | 65 | 8 years | |
| Ashleigh Barreto | F | - | 3 years | |
| Stewart M. Brown | M | - | 2 years | |
| Richard Ghalie | M | 66 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 9 years |
| Sam Murphy | M | 47 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
| Ayman El-Guindy | M | - | 3 years | |
| Patric Nelson | M | - | 3 years | |
| Biljana Nadjsombati | F | - | 3 years | |
| Darrel Cohen | M | 59 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kleanthis Xanthopoulos | M | 66 | 8 years | |
| Paul Grint | M | 66 | 3 years | |
| David Szekeres | M | 50 | 1 years | |
| Shelly Vandertie | F | - | - | |
| Mark Deeg | M | - | - | |
| Mark Foletta | M | 63 | 5 years | |
| Nicole Onetto | M | 71 | 2 years | |
| Bruce Carter | M | 80 | 3 years | |
| John Maraganore | M | 60 | 7 years | |
| Simos Simeonidis | M | 54 | 3 years | |
| Allison Wey | F | - | 2 years | |
| Amy Conrad | F | - | - | |
| Lisa Rojkjaer | M | 58 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 3 years |
| David Slack | M | 61 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
| Michael M. Mueller | M | - | 2 years | |
| Neil Gibson | M | 67 | 4 years | |
| Timothy M. Wright | M | 69 | 3 years | |
| Michael Huang | M | - | - | |
| Douglas Williams | M | 66 | 5 years | |
| B. Parshall | F | 70 | 6 years | |
| Garry Menzel | M | 59 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 49 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Chevallard
- Personal Network
